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February 21, 2012:776–8reflects an association with remodeling or a primary role of
dyssynchrony itself remains to be determined.
The consistency of these clinical characteristics for predicting
recovery, in particular gender, QRS duration, and the degree of
remodeling (LVEDD), does support the concept of a “recovery
score” advocated by the Ohio State group. If prospectively vali-
dated, this would be of great assistance to clinicians in the
management of subjects with recent-onset cardiomyopathy. We
thank Dr. Binkley for his insightful comments.
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Angiotensin-Converting Enzyme
Inhibitors Can Increase the
Transvalvular Gradient Among
Patients With Aortic Stenosis
We read with interest the study of Herrmann et al. (1) that
examined the longitudinal left ventricular (LV) function, degree of
myocardial fibrosis, hemodynamic distinctions, and clinical out-
comes of symptomatic patients attributed to isolated aortic stenosis(AS). The patients were grouped and analyzed according to aortic
valve area, transvalvular gradient, and left ventricular ejection
fraction (LVEF); all patients with severe AS, regardless of trans-
valvular gradient, underwent aortic valve replacement.
We respectfully point out that the proportion of patients on
medical therapy with angiotensin-converting enzyme (ACE)
inhibitors, aldosterone antagonists, beta-blockers, and/or st-
atins at baseline and on follow-up 9 months later was not
reported. This information is important because these medica-
tions can potentially affect the outcomes being evaluated. We
would like to focus our comments regarding ACE inhibitor use,
specifically.
The preoperative use of ACE inhibitors can potentially affect
the outcome of the study by altering 2 factors considered for
patient assignment: transvalvular gradient and LVEF. Since resis-
tance in a series is additive, ACE inhibitors will decrease systemic
vascular resistance through arterial vasodilation, which in turn may
increase the transvalvular gradient (2). These agents are also
established reverse remodeling agents and can improve the LVEF
of patients with systolic dysfunction with long-term use. Although
previously thought to be a contraindication for patients with AS
because of the theoretical concern for hypotension, decreased
coronary perfusion, and renal insufficiency, several prospective
studies suggest that medical therapy with ACE inhibitors may be
safe (2,3). Dalsgaard et al. (4) recently demonstrated with a small
randomized controlled trial that the use of trandolapril among
patients with severe AS did not cause adverse outcomes or symptom-
atic hypotension. Over 8 weeks of follow-up, treatment with tran-
dolapril led to a decrease in LV end-systolic volume and N-terminal
pro–B-type natriuretic peptide, suggesting beneficial effect of ACE-
induced LV unloading (4). The study of Herrmann et al. (1) also
showed that the sickest patient subgroups (i.e., those with low-
gradient severe symptomatic AS, regardless of ejection fraction) have
the highest systemic vascular resistance and relatively preserved blood
pressure. It is plausible that medical therapy with ACE inhibitors
could potentially be used as a bridge to aortic valve surgery.
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